Carfilzomib-d<sub>8</sub>

Carfilzomib-d8

CAT N°: 22558
Price:

From 237.00 201.45

Carfilzomib-d8 is intended for use as an internal standard for the quantification of carfilzomib (Item No. 17554) by GC- or LC-MS. Carfilzomib is an irreversible proteosome inhibitor classified as a peptide epoxyketone. It targets the chymotrypsin-like ?5 subunit of the constitutive 20S proteasome (IC50 = 5.2 nM) and the ?5i subunit of the immunoproteasome 20Si (LMP7; IC50 = 14 nM) with minimal cross reactivity to other proteases.{28244,28242} It can induce cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma, lymphoma, and various solid tumors (IC50s = 2.4-20 nM).{25593,28537}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (?S)-?-[[2-(4-morpholinyl-2,2,3,3,5,5,6,6-d8)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
  • Correlated keywords
    • deuterated deuterium gases chromatography isotope GC/MS LC-MS LC/MS GCMS LCMS PR171 kyprolis PR-171 b5 b5i LMP-7 low-molecular mass protein
  • Product Overview:
    Carfilzomib-d8 is intended for use as an internal standard for the quantification of carfilzomib (Item No. 17554) by GC- or LC-MS. Carfilzomib is an irreversible proteosome inhibitor classified as a peptide epoxyketone. It targets the chymotrypsin-like ?5 subunit of the constitutive 20S proteasome (IC50 = 5.2 nM) and the ?5i subunit of the immunoproteasome 20Si (LMP7; IC50 = 14 nM) with minimal cross reactivity to other proteases.{28244,28242} It can induce cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma, lymphoma, and various solid tumors (IC50s = 2.4-20 nM).{25593,28537}

We also advise you